drugset / Trial / NCT01145508
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized phase II trial studies how well docetaxel and prednisone with or without vaccine therapy works in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vaccines made from an antigen may help the body build an effective immune response to kill tumor cells. It is not yet known whether docetaxel and prednisone are more effective with or without vaccine therapy in treating prostate cancer.
Timeline
- Start
- 2010-08
- Primary completion
- 2012-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PROSTVAC-V | Vaccine | — | Subcutaneous |
| Subject | Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine | Unknown | — | Subcutaneous |
| Background | Docetaxel | Small molecule | — | Intravenous |
| Background | Prednisone | Other / unclassified | — | Oral |